The long noncoding RNA CARDINAL attenuates cardiac hypertrophy by modulating protein translation
Open Access
- 14 May 2024
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (13)
Abstract
One of the features of pathological cardiac hypertrophy is enhanced translation and protein synthesis. Translational inhibition has been shown to be an effective means of treating cardiac hypertrophy, although system-wide side effects are common. Regulators of translation, such as cardiac-specific long noncoding RNAs (lncRNAs), could provide new, more targeted therapeutic approaches to inhibit cardiac hypertrophy. Therefore, we generated mice lacking a previously identified lncRNA named CARDINAL to examine its cardiac function. We demonstrate that CARDINAL is a cardiac-specific, ribosome-associated lncRNA and show that its expression was induced in the heart upon pathological cardiac hypertrophy and that its deletion in mice exacerbated stress-induced cardiac hypertrophy and augmented protein translation. In contrast, overexpression of CARDINAL attenuated cardiac hypertrophy in vivo and in vitro and suppressed hypertrophy-induced protein translation. Mechanistically, CARDINAL interacted with developmentally regulated GTP-binding protein 1 (DRG1) and blocked its interaction with DRG family regulatory protein 1 (DFRP1); as a result, DRG1 was downregulated, thereby modulating the rate of protein translation in the heart in response to stress. This study provides evidence for the therapeutic potential of targeting cardiac-specific lncRNAs to suppress disease-induced translational changes and to treat cardiac hypertrophy and heart failure.Keywords
Funding Information
- National Key Research and Development Program of China (2021YFA1302500)
- Guangzhou Municipal Science and Technology Bureau (202206010139)
- National Natural Science Foundation of China (82270252)
- National Natural Science Foundation of China (81873463)
- National Natural Science Foundation of China (82000385)
- Basic and Applied Basic Research Foundation of Guangdong Province (2019B151502003)
- National Institutes of Health (R01HL149401)
- National Institutes of Health (R01HL138757)
- National Institutes of Health (R01HL165794)
- Foundation for the National Institutes of Health (R01HL168900)
- Additional Ventures (1014383)
This publication has 54 references indexed in Scilit:
- Disruption of ROCK1 gene attenuates cardiac dilation and improves contractile function in pathological cardiac hypertrophyJournal of Molecular and Cellular Cardiology, 2008
- Identification of DRG family regulatory proteins (DFRPs): specific regulation of DRG1 and DRG2Genes to Cells, 2005
- Inhibition of mTOR Signaling With Rapamycin Regresses Established Cardiac Hypertrophy Induced by Pressure OverloadCirculation, 2004
- Phosphorylation of Eukaryotic Translation Initiation Factor 2Bε by Glycogen Synthase Kinase-3β Regulates β-Adrenergic Cardiac Myocyte HypertrophyCirculation Research, 2004
- Na+/H+ exchange inhibition attenuates left ventricular remodeling and preserves systolic function in pressure‐overloaded heartsBritish Journal of Pharmacology, 2004
- Rapamycin Attenuates Load-Induced Cardiac Hypertrophy in MiceCirculation, 2003
- Inhibition of Na + -H + Exchange Prevents Hypertrophy, Fibrosis, and Heart Failure in β 1 -Adrenergic Receptor Transgenic MiceCirculation Research, 2002
- A Calcineurin-Dependent Transcriptional Pathway for Cardiac HypertrophyCell, 1998
- DRG: A novel developmentally regulated GTP-binding proteinBiochemical and Biophysical Research Communications, 1992
- A rapid and convenient technique for measuring the rate of protein synthesis in tissues by injection of [3H]phenylalanineBiochemical Journal, 1980